Asset Details
Do you wish to reserve the book?
SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
Do you wish to request the book?
SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
2021
Overview
Coronavirus disease 2019 (COVID-19) outbreak is proving to be an unprecedented disaster that lays its dark shadow on global health, economics and personal freedom. Severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS) epidemics provide scientific data that is useful in better understanding and resolution of COVID-19. Similarities among SARS-CoV, MERS-CoV and SARS-CoV-2 have been investigated in the light of available data. SARS-CoV, MERS-CoV and SARS-CoV-2 evolved in bats and have positive-sense RNA genomes of 27.9 kb, 30.1 kb and 29.9 kb, respectively. Molecular and serological tools used for diagnosis of SARS and MERS patients resemble COVID-19 diagnostic tools. Stability and longevity data of SARS and MERS epidemics contribute in the current pandemic precaution policies. Trials to produce vaccines for SARS-CoV and MERS-CoV failed, therefore different strategies were employed for SARS-CoV2 vaccines production and during the past period antiviral agents, Convalescent plasma and monoclonal antibodies provide potential treatments for sever patients. The mortality rate caused by the SARS-CoV and MERS-CoV reached 15% and 37%, respectively. The first declarations about mortality rate of SARS-CoV-2 was around 2-4% but now this rate differed globally and reached more than 13% in some countries. A realistic COVID-19 outbreak scenario suggest that the pandemic might last for three years with fluctuation in the number of infected cases, unless vaccination process goes faster and/or antiviral drug is discovered.
Publisher
Elsevier Limited,Chang Gung University
Subject
/ Aged
/ Coronavirus Infections - epidemiology
/ Coronavirus Infections - mortality
/ Coronavirus Infections - therapy
/ COVID-19
/ Enzymes
/ Female
/ Females
/ Humans
/ Male
/ Middle East respiratory syndrome
/ Severe Acute Respiratory Syndrome - epidemiology
/ Severe Acute Respiratory Syndrome - mortality
/ Severe Acute Respiratory Syndrome - therapy
/ Severe acute respiratory syndrome coronavirus 2
/ Vaccines
